An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes Mellitus

This study has been completed.
Eli Lilly and Company
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: July 14, 2009
Last updated: February 23, 2015
Last verified: January 2015
The aim of this study is to assess the long-term safety of exenatide in patients with type 2 diabetes who were treated with exenatide in Study H8O-MC-GWAA (6-month study) or Study H8O-MC-GWAD (12-month study). Study H8O-MC-GWAN serves as an open-ended extension to Studies H8O-MC-GWAA and H8O-MC-GWAD.

Condition Intervention Phase
Type 2 Diabetes Mellitus
Drug: exenatide
Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes Mellitus

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Long-term safety of twice-daily exenatide treatment, as defined by the occurrence of adverse events. [ Time Frame: 128 weeks (average treatment period) ] [ Designated as safety issue: No ]
    Visits for this study occur at 6-mo (±2 wk) intervals until exenatide is approved for marketing.

Enrollment: 275
Study Start Date: December 2003
Study Completion Date: July 2008
Primary Completion Date: July 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Group A
Exenatide injection 5mcg or 10 mcg, twice daily
Drug: exenatide
subcutaneous injection, 5mcg or 10 mcg, twice daily
Other Name: Byetta


Ages Eligible for Study:   30 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients received exenatide therapy in Study H8O-MC-GWAA or Study H8O-MC-GWAD and completed the respective study.

Exclusion Criteria:

  • Patients were excluded or discontinued early from Study H8O-MC-GWAA or Study H8O-MC-GWAD.
  • Patients have received treatment within the last 30 days with a drug, not including exenatide, that has not received regulatory approval for any indication at the time of study entry.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01876849

United States, Washington
Research Site
Renton, Washington, United States
Sponsors and Collaborators
Eli Lilly and Company
Study Director: Chief Medical Officer, MD Eli Lilly and Company
  More Information

Responsible Party: AstraZeneca Identifier: NCT01876849     History of Changes
Other Study ID Numbers: H8O-MC-GWAN 
Study First Received: July 14, 2009
Last Updated: February 23, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by AstraZeneca:

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Hypoglycemic Agents
Physiological Effects of Drugs processed this record on May 25, 2016